Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Precision BioSciences Inc

DTIL
Current price
0.41 USD -0.005 USD (-1.22%)
Last closed 0.41 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 43 411 276 USD
Yield for 12 month -65.97 %
Week
Month
Year
DTIL
21.11.2021 - 28.11.2021

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Address: 302 East Pettigrew Street, Durham, NC, United States, 27701

Analytics

WallStreet Target Price

2.63 USD

P/E ratio

Dividend Yield

Current Year

+25 098 000 USD

Last Year

+115 529 000 USD

Current Quarter

+13 120 000 USD

Last Quarter

+19 789 000 USD

Current Year

+25 098 000 USD

Last Year

+115 529 000 USD

Current Quarter

+13 120 000 USD

Last Quarter

+19 789 000 USD

Key Figures DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -71 515 000 USD
Operating Margin TTM -94.23 %
PE Ratio
Return On Assets TTM -22.65 %
PEG Ratio
Return On Equity TTM -153.82 %
Wall Street Target Price 2.63 USD
Revenue TTM 52 287 000 USD
Book Value 0.25 USD
Revenue Per Share TTM 0.46 USD
Dividend Share
Quarterly Revenue Growth YOY 78.2 %
Dividend Yield
Gross Profit TTM 25 098 000 USD
Earnings Share -0.86 USD
Diluted Eps TTM -0.86 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -140.61 %

Dividend Analytics DTIL

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation DTIL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.0292
Price Sales TTM 0.8302
Enterprise Value EBITDA 0.7219
Price Book MRQ 1.4937

Financials DTIL

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators DTIL

For 52 weeks

0.28 USD 1.45 USD
50 Day MA 0.35 USD
Shares Short Prior Month 606 898
200 Day MA 0.62 USD
Short Ratio 0.83
Shares Short 852 522
Short Percent 0.82 %